Form 4: TERN Director Opts for Equity Over Cash Compensation

Terns Pharmaceuticals director Radhika Tripuraneni elected to receive 1,697 stock options in lieu of a $45,000 cash retainer for 2026, aligning her interests with shareholders.

Summary

• Radhika Tripuraneni, a Director at Terns Pharmaceuticals, Inc. (TERN), acquired 1,697 stock options.
• These options were granted on February 1, 2026, with an exercise price of $34.6 per share.
• The options were issued under the company's Non-Employee Director Compensation Policy.
• The Director chose to receive these options instead of a $45,000 cash retainer fee for the year 2026.
• The options will vest monthly, with 1/12th of the total shares vesting on each monthly anniversary from January 1, 2026, leading to full vesting by January 1, 2027.
• The options have an expiration date of January 31, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies a director's commitment to the company's long-term success by choosing equity over cash, aligning their financial interests with shareholders.

Positives

• Director Radhika Tripuraneni's election to receive stock options instead of cash compensation for her 2026 retainer fee demonstrates a strong alignment of her interests with those of the company's shareholders.
• The issuance of 1,697 stock options ties the director's personal financial incentives directly to the long-term performance and stock value of Terns Pharmaceuticals.

Future Outlook

The stock options granted will vest over a one-year period, with 1/12th vesting monthly from January 1, 2026, until fully vested on January 1, 2027. The options have a long-term expiration date of January 31, 2036.

Management Comments

• "This option was issued pursuant to the Issuer's Non-Employee Director Compensation Policy, under which the Reporting Person elected to receive this option in lieu of the Reporting Person's cash retainer fee of $45,000 for 2026."

Industry Context

StockSavvy.ai notes that the election by a director to receive equity compensation over cash is a common practice in the biotechnology and pharmaceutical sectors, particularly for growth-oriented companies like Terns Pharmaceuticals. This strategy is often employed to conserve cash and to further align the interests of board members with long-term shareholder value creation, a trend widely observed across industries seeking to incentivize performance and commitment.

Comparison to Industry Standards

• The practice of non-employee directors receiving a portion or all of their compensation in equity is a well-established standard across various industries, including biotech. For example, many directors at peer companies such as Gilead Sciences or Amgen often receive a significant portion of their compensation in restricted stock units or stock options to align their incentives with long-term company performance.
• The vesting schedule of 1/12th monthly over a year is also a common structure for director equity grants, ensuring continued engagement and commitment over the compensation period.

Stakeholder Impact

• Shareholders: Potentially positive, as the director's interests are more closely aligned with increasing shareholder value.
• Company: Conserves cash by issuing equity instead of a cash payment for director compensation.

Next Steps

• The stock options will vest monthly, with full vesting expected by January 1, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction related to director compensation. While the director's choice to receive equity over cash is a positive signal of alignment, it does not provide new fundamental information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals.

Keywords

Terns Pharmaceuticals, TERN, Form 4, Insider Transaction, Stock Option, Director Compensation, Equity Compensation, Beneficial Ownership, SEC Filing